Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias

Blood

Volumn 118, Issue 20, 2011, Pages 5697-5700

  Nicolini, Franck Emmanuel ^a,b,c,d   Basak, Grzegorz W ^d,e   Soverini, Simona ^f   Martinelli, Giovanni ^f   Mauro, Michael J ^g   Müller, Martin C ^h   Hochhaus, Andreas ⁱ   Chuah, Charles ^j,k   Dufva, Inge H ^l   Rege Cambrin, Giovanna ^m   Saglio, Giuseppe ^d,m   Michallet, Mauricette ^a,b,c,d   Labussière, Hélène ^a,c   Morisset, Stéphane ^a   Hayette, Sandrine ^b,n   Etienne, Gabriel ^b,o   Olavarria, Eduardo ^p   Zhou, Wei ^q   Peter, Senaka ^q   Apperley, Jane F ^d,r   Cortes, Jorge ^s   more..

^a EDOUARD HERRIOT HOSPITAL   (France)

^b French intergroup for CML (Fi LMC group)   (France)

^c SociétéFrançaise de Greffe de Moelle et de Thérapie Cellulaire SFGM TC   (France)

^d European Society for Blood and Marrow Transplantation Statistical Unit   (Netherlands)

^e MEDICAL UNIVERSITY OF WARSAW   (Poland)

^f UNIVERSITY OF BOLOGNA   (Italy)

^g OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^h UNIVERSITY OF HEIDELBERG   (Germany)

ⁱ JENA UNIVERSITY HOSPITAL   (Germany)

^j SINGAPORE GENERAL HOSPITAL   (Singapore)

^k DUKE NUS MEDICAL SCHOOL   (Singapore)

^l UNIVERSITY OF COPENHAGEN   (Denmark)

^m UNIVERSITY OF TURIN   (Italy)

ⁿ CENTRE HOSPITALIER LYON SUD   (France)

^o INSTITUT BERGONIÉ   (France)

^p Universidad Pública de Navarra   (Spain)

^q MERCK RESEARCH LABORATORIES   (United States)

^r IMPERIAL COLLEGE LONDON   (United Kingdom)

^s UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC MYELOID LEUKEMIA; DONOR; FEMALE; FOLLOW UP; GENE MUTATION; HAZARD RATIO; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; T315I CHROMOSOME;

EID: 80755185510     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-07-367326     Document Type: Article

References (18)

1. O'Hare T, Walters DK, Stoffregen EP, et al. In vitro activity of Bcr-Abl inhibitors AMN107, and BMS 354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res. 2005;65(11):4500-4505. (Pubitemid 40740783)
2. Nicolini FE, Mauro M, Martinelli G, et al. Epidemiologic study on survival of chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia patients with BCR-ABL T315I mutation. Blood. 2009;114(26):5271-5278.
3. Jabbour E, Cortes J, Kantarjian H, et al. Allogeneic stem cell transplantation for patients with chronic myeloid leukaemia and acute lymphocytic leukaemia after Bcr-Abl mutation-related imatinib failure. Blood. 2006;108(4):1421-1423. (Pubitemid 44232047)
4. Velev N, Cortes J, Champlin R, et al. Stem cell transplantation for patients with chronic myeloid leukemia resistant to tyrosine kinase inhibitors with BCR-ABL kinase domain mutation T315I. Cancer. 2010;116(15):3631-3637.
5. Gratwohl A, Brand R, Apperley J, et al. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results: an analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica. 2006;91(4):513-521.
6. Baccarani M, Saglio G, Goldman J, et al.; European LeukemiaNet. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006;108(6):1809- 1820. (Pubitemid 44394987)
7. Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009;27(35):6041-6051.
8. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348(11):994-1004. (Pubitemid 36302244)
9. Nicolini FE, Hayette S, Corm S, et al. Clinical outcome of 27 imatinib mesylate-resistant chronic myelogenous leukemia patients harboring a T315I BCR-ABL mutation. Haematologica. 2007;92(9):1238-1241. (Pubitemid 350144183)
10. Soverini S, Colarossi S, Gnani A, et al. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia positive patients: by the GIMEMAWorking Party on Chronic Myeloid Leukemia. Clin Cancer Res. 2006;12(24):7374-7379. (Pubitemid 46095411)
11. Nicolini F, Corm S, Lê QH, et al. Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(phi)-LMC group). Leukemia. 2006;20(6):1061-1066. (Pubitemid 43797298)
12. Jabbour E, Kantarjian H, Jones D, et al. Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy. Blood. 2008;112(1):53-55.
13. Jabbour E. Kantarjian H, Jones D, et al. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia. 2006;20(10):1767-1773.
14. Legros L, Hayette S, Nicolini FE, et al. BCR-ABLT315I transcript disappearance in an imatinib- resistant CML patient treated with homoharringtonine: a new therapeutic challenge? Leukemia. 2007;21(10): 2204-2206. (Pubitemid 47423816)
15. de Lavallade H, Khorashad J, Davis HP, et al. Interferon-α or homoharringtonine as salvage treatment for chronic myeloid leukemia patients who acquire the T315I BCR-ABL mutation. Blood. 2007;110(7):2779-2780. (Pubitemid 47523217)
16. Nicolini FE, Chomel J-C, Roy L, et al. The durable clearance of the T315I BCR-ABL mutated clone in chronic phase chronic myelogenous leukemia patients on omacetaxine allows tyrosine kinase inhibitor rechallenge. Clin Lymphoma Myeloma Leuk. 2010;10(5):394-399.
17. Cortes-Franco J, Khoury HJ, Nicolini FE, et al. Safety and efficacy of subcutaneous-administered omacetaxine mepesuccinate in imatinib-resistant chronic myeloid leukemia (CML) patients who harbor the BCR-ABL T315I mutation: results of an ongoing multicenter phase 2/3 study [abstract]. Blood. 2009;114(22):267. Abstract 644.
18. Cortes J, Talpaz M, Bixby D, et al. A phase I trial (AP 24534) in patients with refractory chronic myelogenous leukemia (CML) and other hematologic malignancies: emerging safety and clinical response findings [abstract]. Blood. 2010;116(21):96. Abstract 210.